HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by McQuade, C. R. Articles by Pai, A. B. Search for Related Content PubMed PubMed Citation Articles by McQuade, C. R. Articles by Pai, A. B.

CHARLESR. MCQUADE, B.A., is Student and Clinical Research Associate; JENNIFER GRIEGO, PHARM.D., is Cardiovascular Pharmacotherapy Resident; JOEA NDERSON, PHARMD., BCPS, is Associate Professor; and AMY BARTON PAI, PHARMD., BCPS, FASN, is Assistant Professor of Pharmacy and Nephrology, University of New Mexico College of Pharmacy, Albuquerque.

Address correspondence to Dr. Pai at the University of New Mexico College of Pharmacy, 1 University of New Mexico, MSC09 5360, Albuquerque, NM 87131 (abpai{at}salud.unm.edu).

Purpose. The case of a patient who developed clinically relevant increases in serum creatinine (SCr) levels while receiving fenofibrate therapy is reported. Summary. Fenofibrate therapy was initiated for a 60-year old Hispanic man with stage 4 chronic kidney disease (CKD) for the treatment of hypertriglyceridemia. Two weeks after taking 48 mg of fenofibrate daily, the patient’s SCr and blood urea nitrogen concentrations increased from 3.0 and 25 mg/dL, respectively, to 3.5 and 30 mg/dL, respectively. His estimated glomerular filtration rate (eGFR) had decreased from 24.8 to 17.9 mL/min/1.73 m2. One month after initiating fenofibrate, his SCr concentration had increased to 3.7 mg/dL, a 32% increase from baseline. Because of persistently high triglyceride concentrations (e.g., 402 mg/dL), the fenofibrate dosage was increased to 145 mg daily. The patient’s SCr concentration rose to 4.7 mg/dL (a 62% increase from baseline), and his eGFR was calculated as 13 mL/min/1.73 m2. The patient was referred by the nephrology service for vascular-access placement in preparation for hemodialysis. Four days after discontinuation of fenofibrate, the patient’s SCr concentration dropped to 3.3 mg/dL and returned to baseline approximately six weeks later, with an eGFR of 20.5 mL/min/1.73 m2. Preparation for hemodialysis was terminated, and the patient’s eGFR remained stable at 20.2 mL/min/1.73 m2 for the 12 months after fenofibrate discontinuation. A score of 4 on the Naranjo et al. probability scale indicated that there was a possible association between fenofibrate and renal dysfunction in this patient. Conclusion. A 60-year-old patient developed renal impairment after receiving fenofibrate for the treatment of hypertriglyceridemia. Index terms: Antilipemic agents; Blood levels; Creatinine; Dosage; Fenofibrate; Glomerular filtration rate; Hypertriglyceridemia; Kidney diseases; Kidney failure; Toxicity